First Head-to-Head Trial of Entyvio vs Humira for UC
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The InflammatoryBowelDisease.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- 1. Vedolizumab (Entyvio) Achieves Superior Rates of Clinical Remission vs Adalimumab (Humira) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis. Takeda. https://www.takeda.com/newsroom/newsreleases/2019/vedolizumab-achieves-superior-rates-of-clinical-remission-vs.-adalimumab-in-first-ever-head-to-head-biologic-clinical-study-in-ulcerative-colitis/. Published March 9, 2019. Accessed March 29, 2019.